Guided Therapeutics, Inc.
(Note: Guided Therapeutics, Inc. withdrew its plans for a NASDAQ uplisting in an SEC filing dated Dec. 2, 2022.)
(Note: This is NOT an IPO. This is an uplisting to the NASDAQ from the OTC Market, where the stock trades under the symbol “GTHP.” IPOScoop has NO CALL on uplistings. Up to 1.2 million shares of common stock at $10 per share will be offered – and up to 240,000 Pre-Funded Warrants to Purchase Shares of Common Stock and 1.2 million warrants to purchase shares of common stock.)
We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.
LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.
Screening for cervical cancer represents one of the most significant demands on the practice of diagnostic medicine. As cervical cancer is linked to a sexually transmitted disease—the human papillomavirus (HPV)—every woman essentially becomes “at risk” for cervical cancer simply after becoming sexually active. In the developing world, there are approximately 2.0 billion women aged 15 and older who are potentially eligible for screening with LuViva. Guidelines for screening intervals vary across the world, but U.S. guidelines call for screening every three years. Traditionally, the Pap smear screening test, or Pap test, is the primary cervical cancer screening methodology in the developed world. However, in developing countries, cancer screening using Pap tests is expensive and requires infrastructure and skill not currently existing, and not likely to be developed in the near future, in these countries.
**Note: Accumulated deficit of $141.9 million as of Sept. 30, 2021.
We currently are seeking regulatory approval to market LuViva in the United States but have not yet received approval from the U.S. Food and Drug Administration (FDA). As of December 31, 2021, we have sold 144 LuViva devices and approximately 76,980 single-use-disposable cervical guides to international distributors.
|Address||5835 Peachtree Corners East, Suite B Norcross, Georgia|
|Phone Number||770) 242-8723|
|View Prospectus:||Guided Therapeutics, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-1.92 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$12.0 mil|
|Manager / Joint Managers||Roth Capital Partners|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|